te.
Isoniazid, INH: Use caution when administering velpatasvir with isoniazid, INH. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Isoniazid is a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Isoniazid, INH; Pyrazinamide, PZA; Rifampin: Avoid coadministration of sofosbuvir, a P-glycoprotein (P-gp) substrate, with inducers of P-gp, such as rifampin. Taking these drugs together may significantly decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. In a single-dose study, coadministration reduced the sofosbuvir Cmax and AUC to 23% and 28% of normal concentrations, respectively. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp), CYP3A4, CYP2B6, and CYP2C8, such as rifampin. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. In a single-dose study, coadministration reduced the velpatasvir Cmax and AUC to 29% and 18% or normal concentrations, respectively. Velpatasvir is a substrate of P-gp, CYP3A4, CYP2B6, and CYP2C8. Use caution when administering velpatasvir with isoniazid, INH. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Isoniazid is a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Isoniazid, INH; Rifampin: Avoid coadministration of sofosbuvir, a P-glycoprotein (P-gp) substrate, with inducers of P-gp, such as rifampin. Taking these drugs together may significantly decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. In a single-dose study, coadministration reduced the sofosbuvir Cmax and AUC to 23% and 28% of normal concentrations, respectively. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp), CYP3A4, CYP2B6, and CYP2C8, such as rifampin. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. In a single-dose study, coadministration reduced the velpatasvir Cmax and AUC to 29% and 18% or normal concentrations, respectively. Velpatasvir is a substrate of P-gp, CYP3A4, CYP2B6, and CYP2C8. Use caution when administering velpatasvir with isoniazid, INH. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Isoniazid is a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Itraconazole: Use caution when administering velpatasvir with itraconazole. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, itraconazole is a potent inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Ivacaftor: Use caution when administering velpatasvir with ivacaftor. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); ivacaftor is a weak inhibitor of P-gp. Ivacaftor is also a weak inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Ketoconazole: Use caution when administering velpatasvir with ketoconazole. Tak |
